Proteome Sciences PLC Investor Presentation
April 01 2021 - 3:34AM
RNS Non-Regulatory
TIDMPRM
Proteome Sciences PLC
01 April 2021
REACH: non-regulatory announcement
1 April 2021
PROTEOME SCIENCES PLC
("Proteome Sciences", "the Group", or "the Company")
Investor Presentation
Proteome Sciences PLC is pleased to announce that Chief
Executive Officer, Dr Mariola Soehngen, will provide a live
presentation relating to the Company's results for the year ended
31 December 2020 via the Investor Meet Company platform on
Thursday, 8 April 2021 at 10.00am BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and
select to meet Proteome Sciences PLC via:
https://www.investormeetcompany.com/proteome-sciences-plc/register-investor
Investors who already follow Proteome Sciences PLC on the
Investor Meet Company platform will automatically be invited.
For further information please contact:
Proteome Sciences plc
Mariola Soehngen M.D., Chief Executive Officer Tel: +44 (0)20 7043 2116
Dr Ian Pike, Chief Scientific Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter - Corporate Tel: +44 (0) 20 3328 5656
Finance
Tony Quirke - Sales and Corporate Broking
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPUUWCUPGURG
(END) Dow Jones Newswires
April 01, 2021 04:34 ET (08:34 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2023 to Apr 2024